Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06694181 · ClinicalTrials.gov registry record
Safe and Explainable AI
A clinical trial of Breast Cancer and Sepsis, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 300,000
- Enrollment target
- 1
- Study location
NCT06694181 is a study of Breast Cancer and Sepsis that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 300,000 participants, above the 2,558-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (11628% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06694181, a study of Breast Cancer and Sepsis, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 300,000 participants
- Enrollment target
- 1
- Study location
Study Summary
While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowledge effectively, making AI recommendations explainable to clinicians, and establishing safety guarantees.
Conditions Studied
Interventions
- OTHER AI-PERSONALIZED CLINICAL DECISION SUPPORT
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300,000 participants |
| Start Date | 2025-11-29 |
| Est. Completion | 2028-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06694181
The ClinicalTrials.gov registry entry for NCT06694181 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,558-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (11628% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AI-PERSONALIZED CLINICAL DECISION SUPPORT is the first listed.
NCT06694181 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06694181 about?
NCT06694181 is a clinical study titled "Safe and Explainable AI". While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowl...
What is the current status of trial NCT06694181?
This trial is currently recruiting. The enrollment target is 300,000 participants. The study started on 2025-11-29. Estimated completion is 2028-11.
What conditions does trial NCT06694181 study?
This clinical trial studies the following conditions: Breast Cancer, Sepsis, Cardiology, Artifical Inteligence.
What interventions are being tested in trial NCT06694181?
The interventions under investigation include: AI-PERSONALIZED CLINICAL DECISION SUPPORT (OTHER).
Who is sponsoring clinical trial NCT06694181?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06694181 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.